Education
About Us
Working with TipRanks
Follow Us
Teva Pharmaceutical Industries Limited (IL:TEVA)
:TEVA
Earnings Data
Report Date
Aug 06, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
227.8Last Year’s EPS
229.4Same Quarter Last Year
Based on 0 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 07, 2025
|% Change Since: 0.00%
|Next Earnings Date:Aug 06, 2025
Earnings Call Sentiment|Positive
The earnings call reflects a positive outlook with strong growth in innovative brands, successful biosimilar launches, and effective financial management, despite some slower growth in generics and potential risks from U.S. tariffs.Company Guidance
During the Q1 2025 earnings call for Teva Pharmaceutical Industries Limited, the company provided robust guidance for the fiscal year and beyond. Revenue for the quarter grew by 5% in local currency terms, reaching $3.9 billion, with adjusted EBITDA up by 3% and non-GAAP EPS rising 8% to $0.52. This marks the ninth consecutive quarter of growth, driven by strong performances from innovative brands like Austedo, Ajovy, and Uzedy, which saw sales increases of 39%, 26%, and 100% respectively. The company raised its revenue guidance for Austedo by $50 million to $1.950 billion for the year. Teva's generic business also grew 3%, and the company is optimistic about future growth from upcoming biosimilar launches. Looking ahead to 2027, Teva aims to achieve a 30% operating margin, supported by projected $700 million in net savings and continued growth in innovative portfolios, while managing OPEX and capital allocation efficiently.Ninth Consecutive Quarter of Growth
Teva reported its ninth consecutive quarter of growth, with revenue up 5% to $3.9 billion and adjusted EBITDA up 3%. Non-GAAP EPS increased by 8% to $0.52.
Innovative Brands Performance
Sales from innovative brands reached $589 million, up 45% over last year, driven by Austedo growing 39% globally, Ajovy up 26% globally, and Uzedy doubling to $39 million.
U.S. Generics and Biosimilars Launch
Teva launched biosimilar versions of Humira and Soliris in the U.S. and plans to launch five more products from 2025 to 2027, emphasizing a strong portfolio strategy.
Strong Financial Management
Teva reduced its gross debt to $16.7 billion from $17.8 billion at the end of the previous year, and maintained a net debt-to-EBITDA ratio just over three times.
Pipeline Progress
Teva is on track to submit olanzapine LAI for approval in the second half of the year and start Phase 3 trials for duvakitug with Sanofi.
IL:TEVA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
IL:TEVA Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 07, 2025 | 6099.00 | 6150.00 | +0.84% |
Jan 29, 2025 | 7960.00 | 6785.00 | -14.76% |
Nov 06, 2024 | 6952.00 | 6650.00 | -4.34% |
Jul 31, 2024 | 6188.00 | 6450.00 | +4.23% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Teva Pharmaceutical Industries Limited (IL:TEVA) report earnings?
Teva Pharmaceutical Industries Limited (IL:TEVA) is schdueled to report earning on Aug 06, 2025, TBA Not Confirmed.
What is Teva Pharmaceutical Industries Limited (IL:TEVA) earnings time?
Teva Pharmaceutical Industries Limited (IL:TEVA) earnings time is at Aug 06, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Teva Pharmaceutical Industries Limited stock?
The P/E ratio of Teva is N/A.
What is IL:TEVA EPS forecast?
IL:TEVA EPS forecast for the fiscal quarter 2025 (Q2) is 227.8.